Thermal stability of the WHO international standard of interferon alpha 2b (IFN-α2b):: Application of new reporter gene assay for IFN-α2b potency determinations

被引:7
|
作者
Caserman, Simon
Menart, Viktor
Das, Rose Gaines
Williams, Stella
Meager, Anthony
机构
[1] Natl Inst Biol Stand & Controls, Biostat Grp, Potters Bar EN6 3QG, Herts, England
[2] Natl Inst Chem, Ljubljana, Slovenia
关键词
thermal stability; interferon-alpha; 2b; bioassays; reporter gene;
D O I
10.1016/j.jim.2006.11.006
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A World Health Organization requirement for biological standards is that they should exhibit long-term stability at their recommended storage temperature. Thermal stability is usually predicted in accelerated thermal degradation studies, where ampoules of the lyophilized standard are stored at elevated temperatures for relatively short times before testing. To confirm the predicted thermal stability of the 2nd international standard of human interferon alpha 2b (IFN-alpha 2b, 95/566), we tested the potency of the ampouled contents of this standard after 9 years storage at the customary storage temperature of -20 degrees C in comparison with ampoules of the IS which had been stored continuously at temperatures ranging from - 150 degrees C to 56 degrees C. Since IFN-alpha 2b potency estimates derived from the results of antiviral assays (AVA) showed high within-assay variability, we investigated a novel reporter gene assay (RGA) based on induction of secreted alkaline phosphatase (SEAP) for comparability and precision of such estimations. We show that this RGA generated comparable estimates with overall lower variation. Additionally, the SEAP conversion of pnitrophenyl phosphate to yellow product could be followed kinetically. Absorbance readings were shown to increase with time in proportion with increasing concentration of IFN-alpha 2b. When the time-dependent increments of absorbance were plotted graphically, the slopes of lines corresponded to concentration. This approach enabled single dilutions of IFN samples, identical in molecular structure to an IFN-alpha 2b standard, to be used for potency estimates by interpolation of slope value against those of the standard at fixed concentrations. It appears attractive for high through-put potency testing of various R&D IFN-alpha 2b samples. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:6 / 12
页数:7
相关论文
共 50 条
  • [31] Intermediate dose interferon alfa 2b (IFN alfa 2b) in adiuvant treatment for malignant melanoma
    Agostara, B.
    Savio, G.
    Calabria, C.
    Leonardi, V.
    Laudani, Agata
    Pepe, A.
    Rondello, G.
    ANNALS OF ONCOLOGY, 2005, 16 : 59 - 60
  • [32] IFN-α2b and thalidomide synergistically inhibit tumor-induced angiogenesis
    Bauer, JA
    Morrison, BH
    Grane, RW
    Jacobs, BS
    Borden, EC
    Lindner, DJ
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2003, 23 (01): : 3 - 10
  • [33] Efficacy and toxicity of IFN-α2b combined with cytarabine in chronic myelogenous leukaemia
    Lindauer, M
    Domkin, D
    Döhner, H
    Kolb, HJ
    Neubauer, A
    Huhn, D
    Kreiter, H
    Koch, B
    Huber, C
    Aulitzky, W
    Fischer, T
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (04) : 1013 - 1019
  • [34] Differing immune effects of PEG-IFN-alpha 2b and IFN-alpha 2b combined with ribavirin for chronic hepatitis C
    Ishii, K
    Sumino, Y
    Higami, K
    Fujita, Y
    Shinohara, M
    Ikehara, T
    Shinohara, M
    Matsumaru, K
    Nagai, H
    Watanabe, M
    Miki, K
    HEPATOLOGY, 2005, 42 (04) : 677A - 678A
  • [35] Comparisons of Pharmacokinetic Profiles of High Dose Interferon-α2b (IFN) and peginterferon-α2b (PEG-IFN) in Melanoma Patients
    Xu, C.
    Daud, A. I.
    DeConti, R. C.
    Floren, L. C.
    Hwu, W. J.
    Guminsk, A.
    Sabesan, S.
    Batageli, E.
    Prasad, P.
    Yver, A.
    Sondak, V. K.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09): : 1122 - 1122
  • [36] Antifibrogenic effect of IFN-α2b on hepatic stellate cell activation by human hepatocytes
    Giannelli, Gianluigi
    Bergamini, Carlo
    Marinosci, Felice
    Fransvea, Emilia
    Napoli, Nicola
    Maurel, Patrick
    Dentico, Pietro
    Antonaci, Salvatore
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2006, 26 (05): : 301 - 308
  • [37] Development of next generation of therapeutic IFN-α2b via genetic code expansion
    Zhang, Bo
    Xu, Huan
    Chen, Jingxian
    Zheng, Yongxiang
    Wu, Yiming
    Si, Longlong
    Wu, Ling
    Zhang, Chuanling
    Xia, Gang
    Zhang, Lihe
    Zhou, Demin
    ACTA BIOMATERIALIA, 2015, 19 : 100 - 111
  • [38] The chemoprotective effects of IFN- α-2b on rat hepatocarcinogenesis are blocked by vitamin E supplementation
    Vera, Marina C.
    Lucci, Alvaro
    Ferretti, Anabela C.
    Abbondanzieri, Adriano A.
    Comanzo, Carla G.
    Lorenzetti, Florencia
    Pisani, Gerardo B.
    Ceballos, Maria P.
    Alvarez, Maria de L.
    Carrillo, Maria C.
    Quiroga, Ariel D.
    JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2021, 96
  • [39] The antifibrogenic effects of liposome-encapsulated IFN-α2b cream on skin wounds
    Takeuchi, M
    Tredget, EE
    Scott, PG
    Kilani, RT
    Ghahary, A
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1999, 19 (12): : 1413 - 1419
  • [40] Pegylated interferon alpha 2b (PEG-IFN) plus ribavirin (RBV) versus pegylated interferon alpha 2b for chronic hepatitis C in HIV patients
    Cargnel, A
    Angeli, E
    Mainini, A
    Gubertini, G
    Giorgi, R
    Orlando, G
    Duca, P
    GASTROENTEROLOGY, 2003, 124 (04) : A766 - A766